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ABSTRACT 
DNA double-strand break (DSB) repair gene products play an important role in 
development and tumor suppression.  Mutations in ATM, BRCA1, BRCA2, MRE11, NBN, 
PALB2, RAD50, RAD51, and XRCC2 result in embryonic lethality or cause pediatric 
diseases including ataxia-telangiectasia, Fanconi anemia (FA), Nijmegen breakage 
syndrome (NBS), and other disorders. 
A DNA DSB can be repaired using two different pathways: nonhomologous end-
joining (NHEJ) and homology-directed DSB repair (HDR).  Some DSB repair proteins, 
including ATM, Mre11, RAD50, and Nibrin, function in both pathways.  RAD51 and its 
paralogs only function in HDR. 
Mre11-Rad50-Nibrin (MRN) complex is a heterohexamer composed of dimers of 
each protein.  The MRN complex is important for early detection of DNA DSBs and 
activates downstream effectors, most notably the protein kinase ATM.  ATM 
phosphorylates other DNA repair proteins including H2AX.  gH2AX, phosphorylated 
histone H2AX, is an important DNA damage signaling factor that helps recruit BRCA1 
to damaged DNA.  XRCC2 helps promote RAD51 foci through interaction with other 
RAD51 paralogs RAD51B, RAD51C, and RAD51D to form the BCDX2 complex. 
FA and NBS-like disorder result from biallelic mutations in XRCC2 and RAD50, 
respectively.  These genetically distinct disorders share many clinical similarities.  Bone 
marrow failure is a key symptom of FA and has been observed in multiple NBS patients.  
iv 
The hematopoietic malignancy acute myeloid leukemia has been observed in patients 
suffering from FA and NBS.  Hormone abnormalities and fertility issues present in both 
patient populations as do issues with growth and development. 
Null mutations in RAD50 and XRCC2 are embryonic lethal in humans and mice, 
so zebrafish was chosen as the model organism to study mutations in each of these genes.  
Null mutations in related genes (e.g., BRCA2) that result in embryonic lethality in 
humans and mice are tolerated in zebrafish.  Frameshift mutations were generated in 
rad50 and xrcc2 using transcription activator-like effector nucleases in zebrafish.  We 
recovered the first viable vertebrate model for biallelic null mutations in RAD50 and 
XRCC2.  Study of these mutants might offer unique insights into human disease that have 
not been possible previously due to a lack of appropriate model systems. 
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Many breast cancer susceptibility genes are members of the DNA double-strand 
break (DSB) repair pathway 1.  Proteins encoded by genes including ATM, BRCA1 and 
BRCA2, the Mre11-Rad50-NBN (MRN) complex genes, and RAD51 and its paralogs 
play a central role in the proper repair of DNA double-strand breaks (DSBs) 1.  
Homozygous mutations in many of these genes result in embryonic lethality in both 
humans and mice or severe childhood diseases such as ataxia-telangiectasia (A-T), 
Fanconi anemia (FA), and Nijmegen breakage syndrome (NBS), which makes it difficult 
to study the roles these genes play in development 2. 
 
DNA double-strand break repair 
There are two main pathways for repair of DNA DSBs: nonhomologous end-
joining (NHEJ) and homology-directed DSB repair (HDR) 3–5.  NHEJ does not require a 
sister chromatid for repair 3.  As a result, repair is much more error prone, often resulting 
in indel and point mutations 3.  HDR is much less error prone because it uses the sister 
chromatid as a template for repair 5.  Because NHEJ does not require a sister chromatid 
while HDR does, cells in G0/G1 can only utilize NHEJ for repair of DSBs 6.  The MRN 
complex acts early enough in the double-strand break repair pathway that it is involved in 
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both NHEJ and HDR, while the FA genes, BRCA1, BRCA2, BRIP1, PALB2, RAD51, 
RAD51C, and XRCC2, are only involved in HDR 3–5. 
An essential protein complex for detection of DNA DSBs is the Mre11-Rad50-
Nibrin (MRN) complex 7,8.  The MRN complex is composed of protein dimers of Mre11, 
RAD50, and Nibrin 9.  Mre11 and Rad50 are conserved in both prokaryotes and archaea 
10.  There are four key domains within the MRN complex: the head, coil, hook, and 
flexible adapter domains 9.  The head domain is composed of a dimer of Mre11 and the 
ATPase domains (Walker A and Walker B) from both RAD50 proteins 9.  The coil and 
hook domains are both composed from Rad50 protein sequence, with the hook domain 
also containing zinc ions 9.  Last, the flexible adapter connects the head domain to Nibrin 
and to the important signaling functions of MRN 9,11.  Disruption of any of these domains 
can severely impact MRN function.  Mre11 functions in binding to damaged DNA, and 
additionally has exo- and endonuclease activity 9,12,13.  Rad50 serves important structural 
roles in the MRN complex through conformational changes due to ATP binding and 
long-range tethering of damaged DNA 7,8,14,15.  Through its forkhead-associated domain 
(FHA) and BRCT domain, Nibrin helps to correctly localize the MRN complex and 
activate downstream effectors, notably ataxia-telangiectasia mutated (ATM) 16–18. 
In response to DNA damage, ATM is recruited to the break site by Nibrin 11,18.  In 
the absence of Nibrin, ATM can phosphorylate H2AX and only transiently phosphorylate 
p53 but cannot phosphorylate its other targets, including Chk2 and BRCA1 11,19,20.  This 
canonical activation has been challenged by recent evidence that ATM can be activated 
by Ku and DNA-PKcs in the absence of the MRN complex 20.  ATM is the main 
mediator of histone H2AX phosphorylation, denoted gH2AX, necessary for proper 
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recruitment of BRCA1 and other proteins to break sites 21,22.  H2AX phosphorylation is 
also modestly important for the recruitment of the MRN complex members (You et al., 
2010).  ATM also phosphorylates Chk2 at Thr68, which induces polymerization of Chk2, 
causing trans-phosphorylation at Thr383 and Thr387, producing activated Chk2 23.  
Activated Chk2 induces cell cycle arrest through phosphorylation of Cdc25A and 
Cdc25C 24,25.  Chk2 also can then phosphorylate BRCA1 at Ser988, which activates the 
HDR pathway 26.  BRCA1 is also phosphorylated by ATM in response to DNA DSBs 27. 
BRCA1 and BARD1 heterodimerize through their RING domains 28.  This 
interaction stabilizes each protein and facilitates early recruitment of BRCA1 to the sites 
of DSBs through the interaction between the BARD1 BRCT domain and poly(ADP-
ribose) 29,30.  BRCA1 interacts with RAD51 at the sites of DNA damage 31.  These foci 
are marked by gH2AX, which is responsible for the recruitment of many factors to the 
DNA break site  32,33.  The exact role that BRCA1 plays at the site of DNA damage is not 
yet fully known.  One hypothesis is that BRCA1 acts as a scaffold for ATM-ATR 
signaling 34,35.  Through interaction with RAD51, BRCA2 mediates strand invasion 36.  
PALB2 facilitates the interaction between BRCA1, BRCA2, and RAD51 at the DNA 
damage site 37. 
XRCC2, which is one of the five RAD51 paralogs, helps promote HDR 38.  The 
other RAD51 paralogs include RAD51B, RAD51C, RAD51D, and XRCC3 38.  Each 
paralog is nonredundant and is necessary for HDR 38–41.  XRCC2 was first identified for 
its ability to complement hypersensitivity to DNA damaging agents seen in the irs1 
Chinese hamster ovary cell line 42,43.  XRCC2 interacts with other RAD51 paralogs 
RAD51B, RAD51C, and RAD51D to form the BCDX2 complex, which promotes 
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RAD51 foci formation 44–49.  The CX3 complex, composed of RAD51C and XRCC3, 
acts downstream of the BCDX2 complex and helps resolve Holliday junctions, a key 
intermediate in homologous recombination 41. 
 
Loss of DSB genes results in severe genetic disorders 
Biallelic mutations in RAD50 and XRCC2 result in the genetic disorders NBS-like 
disease and FA, respectively 50–52.  While NBS-like disease and FA are distinct genetic 
disorders, there are overlapping clinical features between the two diseases 53.  Bone 
marrow failure has been reported in several NBS patients and is a key feature in FA 54–57.  
Acute myeloid leukemia (AML) develops in patients suffering from each disease as well 
54,58–60.  Patients suffering from FA or NBS exhibit growth retardation, microcephaly, and 
defects of the thumbs 53,61–67.  Female FA and NBS patients both present with primary 
ovarian insufficiency 68,69.  Hormone abnormalities are also observed in both FA and 
NBS patients, including elevated follicle stimulating hormone (FSH) levels 69,70. 
 
NBS and NBS-like disease 
The MRN complex and downstream target ATM all result in diseases with similar 
cellular phenotypes when the genes are mutated.  A-T is caused by biallelic mutations in 
ATM 71.  Biallelic MRE11 mutations cause the related A-T-like disorder 72.  Biallelic 
mutations in NBN and RAD50 result in the similar diseases NBS and NBS-like disorder, 
respectively 50,61,62.  Given the interactions between these genes, it is not surprising that 
they share many cellular phenotypes.  Chromosomal instability, radiosensitivity, 
radioresistant DNA synthesis, and defective G1/S and G2/M checkpoints are all hallmarks 
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of both NBS and NBS-like disorder at the cellular level 73.  A-T patients suffer from 
ataxia, which is loss of motor control, and telangiectasia, a condition characterized by 
dilated blood vessels below the skin 73.  These symptoms, in addition to cerebellar 
degeneration, are not present in NBS patients 61,62,73.  A-T patients do share some 
symptoms with NBS patients, namely ovarian dysgenesis, immunodeficiency, cancer 
predisposition, and growth retardation, though to a lesser extent than what is seen in NBS 
patients 73.   
Homozygous null RAD50 mutations are lethal in mice 74.  One human patient 
presented with NBS but did not carry two mutant alleles in NBN 50,75.  Instead, this 
patient, who was not the result of a consanguineous marriage, carried two different 
RAD50 mutations, a nonsense mutation (c.3277C→T; p.R1093X) and a loss of the stop 
codon (c.3939A→T) 50.  The patient presented with less than 5% RAD50 protein level 
compared to wild type 50.  Most of our knowledge about NBS comes from patients with 
NBN mutations because there currently exists only one human patient that presented with 
biallelic RAD50 mutations, and this patient is likely only able to survive because they do 
not have a complete loss of RAD50.  A founder mutation (c.657_661del5) exists in NBN 
in Slavic populations, making the disease most common in those populations 67.  We 
know from NBS patients that issues with the hematopoietic system exist, namely two 
cases of bone marrow aplasia in unrelated Russian NBS patients and aplastic anemia in a 
Japanese child with NBS 54,55.  These findings of bone marrow defects are observed in a 
mouse model that contains a hypomorphic Rad50 mutant allele, dubbed the Rad50S 
allele 76,77.  Rad50S/S mice show growth retardation that is due to hematopoietic failure, 
and one mouse developed myeloid leukemia, a cancer type observed in human NBS 
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patients 54,76.  These findings illustrate that mouse hypomorphic Rad50 mutants show 
multiple phenotypes consistent with human NBS, further supporting that biallelic RAD50 
mutations cause NBS-like disease. 
 
Fanconi anemia 
FA is a genetic disease caused by mutations in any of 21 different genes involved 
in DNA interstrand cross-links (ICL) repair or HDR 52,78–82.  Nineteen of the genes act as 
autosomal recessive genes, while FANCB is the lone X-linked recessive FA gene and 
RAD51 (FANCR) is the lone autosomal dominant FA gene 79,80,83.  As mentioned 
previously, FA is genetically distinct from NBS, yet both diseases share many common 
symptoms. 
Repair of interstrand cross-links is the least understood form of DNA repair for 
two main reasons: the difficulty in creating cross-links to study, and the fact that different 
cross-links are repaired differently 84.  Replication protein A (RPA) has been shown to 
recognize interstrand cross-links caused by the platinum-based chemotherapy drug 
cisplatin 85.  Phosphorylation of FANCM recruits the rest of the FA core complex to 
chromatin 86.  The FA core complex is composed of FANCA, FANCB, FANCC, FANCE, 
FANCF, FANCG, FANCL, and FANCM and promotes monoubiquitination of the ID2 
complex 86.  Monoubiquitination of the ID2 complex, composed of FANCI and FANCD2, 
activates the complex.  The exact function of the ID2 complex has not been fully 
elucidated.  XPF and ERCC1 are both involved in ICL to fix cross-link-induced double-
strand breaks through “unhooking” (chemical cleavage) of the cross-link 87–89.  This event 
depends on ubiquitination of FANCD2 and interaction with SLX4 (FANCP) 89.  Protein 
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encoded by the HDR genes, including breast/ovarian cancer susceptibility genes BRCA1, 
BRCA2, BRIP1, PALB2, RAD51C, and XRCC2 are all involved in ICL to fix DSBs and 
are recessive FA genes 52,78,90–93. 
A 2.5-year-old Saudi child presented with a case of FA but did not have a 
mutation in any of the known FA genes 51.  Whole-exome sequencing identified a 
homozygous nonsense mutation (p.Arg215*) in XRCC2 51.  In 2016, further research 
showed that XRCC2 could complement the cellular defects in this patient’s fibroblasts 
that are hallmarks of FA cells, namely hypersensitivity to DNA interstrand crosslinking 
agents, overabundance of cells in G2-M phase of the cell cycle, and chromosome 
breakage, illustrating that the XRCC2 mutation is the causative mutation in this patient 52. 
 
Development of assays for determining pathogenicity of missense 
substitutions in DSB repair genes 
Effectively determining pathogenicity of unclassified missense substitutions is 
essential for clinical mutation screening.  There are two types of variants of uncertain 
significance (VUS): variants that are unclassified and variants that are 
uncertain.  Unclassified variants are sequence variants that have not previously 
undergone evaluation for pathogenicity.  Uncertain variants are sequence variants that 
either do not have enough evidence to classify as pathogenic or neutral or have 
contradicting evidence for or against pathogenicity.  With more mutation screening being 
performed via panel testing, the possibility of finding a VUS increases.  Our lab’s data 
suggest that for the breast cancer susceptibility genes RAD50 and XRCC2, roughly 50% 
of the genetic risk attributable to these genes is caused by rare missense substitutions 94–
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96.  This presents significant challenges to screening patients in the clinic.  In an attempt 
to determine the pathogenicity of VUS in intermediate-risk breast cancer susceptibility 
genes, we planned to develop a functional assay to test different mutations found 
previously by the lab during case-control mutation screening of human breast cancer 
patients 94–97.  To attempt to develop a system to assay variants in RAD50 and XRCC2, 
we planned to use zebrafish as our model organism. 
 
Zebrafish model 
While the sequence analysis and family study-based components of missense 
substitution evaluation that were developed for BRCA1 and BRCA2 also apply to RAD50 
and XRCC2, we believe that medium throughput functional assays will play a critical role 
to decrease the number of VUS in these two genes 98–101.  Many of the key DNA double-
strand break repair genes are conserved in zebrafish 102,103.  Zebrafish offer a unique 
model because null mutations in genes including brca2, which would be lethal in 
mammals, are tolerated in zebrafish 104–106.  The other benefit of using zebrafish is the 
power of embryo injection assays, allowing mRNAs containing sequence variants of 
interest to be injected into mutant zebrafish. 
Results from the embryo injection functional assays can be combined with in 
silico predictions and patient family history to perform an integrated evaluation of each 
missense substitution 98–101.  Functional assays have already been conducted on some 
CHEK2 sequence variants 23,107.  RNA injection experiments are beginning to be 
performed in zebrafish to assess the pathogenicity of rare missense substitutions in kcnh2 
and hcn4, genes involved in Long QT syndrome and Sick Sinus Syndrome, respectively 
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108,109.  Methods exist for rapid generation of many mRNAs containing the missense 
substitutions of interest using the methods described in Drost et al., 2010 110.  As 
radiosensitivity is a phenotype for both RAD50 and XRCC2, we planned to assay cleaved 
Caspase-3 via whole-mount immunofluorescence and perform western blots for gH2AX 
following irradiation 111,112.  Both genes are involved in DNA DSB repair, so we also 
planned to utilize a damaged GFP assay to quantify changes in HDR 113. 
To develop lines to assay our human sequence variants, we first needed to 
generate null mutations in the zebrafish copies of rad50 and xrcc2.  We used 
transcription activator-like effector nucleases (TALENs) to create mutations in these 
genes.  TALENs function by creating a double-strand break at a specific sequence 114.  If 
this break is repaired by NHEJ, then there is the possibility of creating a frameshift 
mutation 114.  For rad50, a 7 base-pair (bp) frameshift mutation was recovered in exon 3, 
disrupting the ATPase-N domain, also resulting in a premature stop codon.  Deletions of 
8 and 10 bp were generated in xrcc2 in the third and final exon in xrcc2, disrupting most 
of the P-loop NTPase domain.  Each of these mutations was eventually characterized. 
Because of the mutant phenotypes associated with rad50 and xrcc2, we were 
unable to assay variants in either gene.  However, these zebrafish mutations turned out to 
be the only existing vertebrate models of null mutations in either gene.  As no research 














 The DNA homologous recombination repair gene XRCC2 is one of 21 different 
genes associated with the disease Fanconi anemia (FA).  Because of embryonic lethality 
in mammals, there is a lack of XRCC2 vertebrate models to study the effects XRCC2 has 
on development and tumorigenesis.  To investigate the biological impact of XRCC2 on 
vertebrates, a zebrafish xrcc2 knockout was generated.  All xrcc2-/- zebrafish develop 
exclusively as males due to female-to-male sex reversal, a pattern consistent with other 
zebrafish FA gene mutants.  xrcc2 is expressed at significantly higher levels in the 
gonads than in other tissues.  The male sex skew was rescued by introducing the 
tp53(M214K) allele, which allowed tp53(M214K/M214K);xrcc2-/- females to develop.  
Testicular neoplasias, specifically seminomas, developed in the xrcc2-/- males beginning 
around roughly 20 months of age, indicating tumor suppressor function of xrcc2 in male 
gonad.  By rescuing the sex skew of xrcc2 and analyzing tumors, we support the findings 








XRCC2 is an important DNA repair gene and has been associated with Fanconi 
anemia (FA).  However, because of embryonic lethality in mammals, few developmental 
models exist to study XRCC2 function.  Because of this, little is known about the role 
XRCC2 plays in later vertebrate development.  Using zebrafish, we report the first viable 
vertebrate model with an XRCC2 mutation. xrcc2 mutant zebrafish exhibit the hallmarks 
of FA gene mutants in zebrafish including female-to-male sex reversal, with all fish 
developing into fertile males.  This male sex skew can be rescued by mutation of tp53 
using the dominant-negative hypomorphic zdf1 (p.Met214Lys) allele, which allows for 
fertile, double mutant females to develop.  xrcc2 is highly expressed in the gonads of 
wild-type zebrafish.  The xrcc2 mutant zebrafish showed 3-fold decreased expression 
(p<0.05) of amh in their testes and 1.2-fold testicular expression (p=0.20) of dmrt1a and 
1.5-fold increased expression (p=0.21) of igf3.  Testicular germ cell tumors also develop 
in the xrcc2 mutants, with approximately 30% incidence by age 23 months. 
 
Introduction 
XRCC2 (X-ray repair cross complementing gene-2, [OMIM 600375]) is a DNA 
homologous-recombination-repair gene as well as a strong candidate moderate risk breast 
cancer susceptibility gene 95.  XRCC2 is one of the five paralogs of the Escherichia coli 
RecA homolog RAD51 and was discovered and cloned based on its ability to rescue the 
DNA damage repair defect in the irs1 Chinese hamster cell line 43.  The five RAD51 
paralogs, RAD51B, RAD51C, RAD51D, XRCC3, as well as XRCC2, are necessary for the 





protein sequence conservation from humans to Trichoplax adhaerens 95.  While several 
studies have failed to replicate the finding of XRCC2 as a breast cancer susceptibility 
gene 116–118, XRCC2 has been shown to interact with the products of breast and/or ovarian 
cancer susceptibility genes RAD51B, RAD51C, and RAD51D as part of the BCDX2 
complex, which is necessary for the formation of RAD51 foci 44–49.  Biallelic mutations in 
RAD51C and XRCC2 have been shown to cause Fanconi anemia 52,79,80,93. 
Fanconi anemia (OMIM 227650) is a rare genetic disease caused by 21 different 
genes involved in interstrand crosslinking (ICL) repair and the interface between ICL 
repair and the homologous recombination repair (HRR) pathway 52,78–82.  Several known 
breast and/or ovarian cancer susceptibility genes are also recessive FA genes (e.g., 
BRCA1, BRCA2, BRIP1, PALB2, and RAD51C) 78,90–93.  Symptoms of FA include bone 
marrow failure, congenital defects, chromosomal instability, hypersensitivity to DNA 
crosslinking agents, and cancer predisposition, including acute myeloid leukemia and 
squamous cell carcinoma of the head and neck 82,119,120.  In a previously unexplained case 
of FA in a 2.5-year-old Saudi child, whole exome sequencing was conducted, and a 
homozygous nonsense mutation (p.Arg215*) in XRCC2 was identified as the likely cause 
51.  It was further shown that three hallmarks of FA cells (hypersensitivity to interstrand 
crosslinking agents, chromosome breakage, and accumulation of cells in G2-M during 
the cell cycle) could all be rescued in primary fibroblasts from that patient by 
complementing with wild-type XRCC2 52.  These findings led to the designation of 
XRCC2 as an FA-like gene, FANCU 52.  Mutations in FA genes have also been shown to 
result in defects in germ cell development and sex determination 104,121–125. 





is achieved in a variety of different ways.  Some vertebrate species rely on sex 
chromosomes or other genetic factors to determine sex. Others use environmental factors 
such as temperature for sex determination, and some species use a combination of both.  
For example, medaka (Oryzias latipes) has XX/XY sex determination but XX females 
can develop into males at high temperatures 126.  Despite being a commonly used model 
organism, the sex determination mechanism in zebrafish (Danio rerio) has not been fully 
elucidated.  While there are no obvious sex chromosomes in zebrafish 127–129, sex 
determination in zebrafish is primarily due to genetic as opposed to environmental factors 
(reviewed in Liew and Orbán 130).  Loss of germ cells, either through ablation or mutation 
of genes including dead end and nanos3, leads to the development of sterile males to the 
exclusion of females; this finding illustrates the requirement of viable oocytes for female 
development in zebrafish and does not appear to depend upon the oogonial stem cells 131–
134.  Additionally, inhibition of aromatase results in the female-to-male sex reversal of 
adult zebrafish 135. 
The FA/BRCA gene network, which is largely intact in zebrafish, has proven to 
be important in zebrafish sex determination 136.  To date, FA genes brca2 (fancd1), fancl, 
and rad51 have been mutated in zebrafish 104,121,125.  All show female-to-male sex 
reversal in homozygous mutants 104,105,121,125 (and reviewed in Rodríguez-Marí and 
Postlethwait 137). Both brca2 and fancl are expressed in the gonads of wild-type 
zebrafish, with brca2 and fancl mutants showing increased germ cell apoptosis 105,121.  
The tp53 mutant allele zdf1 (p.Met214Lys), which is a dominant-negative hypomorphic 
allele, complements the brca2, fancl, and rad51 developmental defect, decreasing germ 









xrcc2-mutant zebrafish are all fertile males due to female-to-male 
sex reversal 
To investigate the role of xrcc2 in zebrafish development and tumorigenesis, a 
transcription activator-like effector nuclease (TALEN) was used to induce a frameshift 
mutation early in exon 3 of xrcc2, disrupting most of the P-loop NTPase domain.  Two 
different frameshifted alleles were generated, an 8-base-pair (bp) and a 10-bp deletion 
(Fig. 2.1A).  The xrcc2 8-bp and 10-bp alleles were genotyped by high-resolution melting 
(HRM) curve analysis (Fig. 2.1B and 2.1C).  xrcc2 heterozygotes were incrossed to 
generate xrcc2 homozygotes.  From 131 incrossed fish, 34 were xrcc2 homozygotes, all 
of which were male.  In contrast, the sex ratios were normal for wild-type and 
heterozygous fish (Fig. 2.2A).  There are two possible explanations for this: female 
lethality or female-to-male sex reversal as seen in brca2, fancl, and rad51 104,121,125.  To 
deduce which was occurring, xrcc2 homozygote males were crossed to xrcc2 
heterozygote females.  For this cross, the number of homozygotes should be equal to 
heterozygotes; however, if the number of homozygotes is significantly smaller, it would 
indicate female lethality.  In the cross, we recovered 112 xrcc2 homozygotes, which were 
again all male, and 108 (77 females and 31 males) heterozygotes (Fig. 2.2B).  This 
finding indicated that the male sex skew in the xrcc2 homozygotes is due to female-to-





xrcc2 is predominantly expressed in the gonads of wild-type zebrafish and 
aberrant gene expression occurs in xrcc2-mutant testes 
Given the female-to-male sex skew in xrcc2 homozygotes, xrcc2 expression was 
compared between wild-type and xrcc2-/- adult flank (posterior of the anal fin), gut, head 
(anterior of the gill slit), and testis tissue.  xrcc2 mRNA was also measured in wild-type 
ovaries.  The frameshift mutation is contained within the third and final exon of xrcc2.  
Nonsense mediated decay (NMD) has been known to be inefficient when the premature 
stop codon is located downstream of the last exon junction complex (EJC) 140. To 
determine xrcc2 expression, quantitative reverse transcription PCR (qRT-PCR) was 
conducted for xrcc2; β-actin was used as the loading control 141.  xrcc2 was expressed 98-
fold higher (p<0.05) in wild-type testis and 75-fold higher (p<0.05) in ovary tissue 
compared to the flank, gut, and head (Fig. 2.3A). 
There was no significant difference (p>0.05) in xrcc2 expression between the 
wild-type flank, gut, or head, and the homozygous mutant flank, gut, or head, indicating 
that the xrcc2 mRNA does not appear to be degraded by NMD in xrcc2 homozygotes.  
Expression of xrcc2 in the homozygous mutant testes was 3-fold lower (p<0.05) than in 
the wild-type testes.  All the xrcc2 transcript from the mutants showed the frameshift 
deletion mutation as detected by HRMA (data not shown). 
Anti-Müllerian hormone (amh) is produced in zebrafish Sertoli cells and is a 
marker of males 142.  We used qRT-PCR to compare amh expression in wild-type and 
xrcc2-/- testes and wild-type ovaries.  Wild-type testes had 3-fold higher expression 
(p<0.05) of amh than the xrcc2-/- testes and 64-fold higher expression (p<0.05) than wild-





than the wild-type ovaries.  We also examined expression of other genes involved in sex 
determination, including doublesex and mab-3 related transcription factor 1a (dmrt1a) 
and insulin-like growth factor 3 (igf3), both of which are important in male germ cell 
biology 143,144.  While neither of these genes were significantly different between wild-
type testis and xrcc2-mutant testis, igf3 had 1.5-fold elevated expression (p=0.21) in the 
xrcc2-mutant testis compared to wild-type (Fig. 2.3C), while dmrt1a expression was 
decreased 1.2-fold (p=0.20) in the xrcc2-mutant testis compared to wild type (Fig. 2.3D). 
 
Mutating tp53 rescues male sex skew in xrcc2 mutants 
Previous studies on FA mutants in zebrafish reported that only a tp53zdf1/zdf1 
background rescued the female-to-male sex skew, allowing for development of viable 
double-homozygote females.  xrcc2 mutants were crossed into a tp53zdf1 background.  
The tp53+/zdf1;xrcc2+/- fish were incrossed, and the offspring were genotyped.  We 
observed tp53 rescue in the xrcc2 mutants, generating 13 double-homozygote females 
(Fig. 2.4).  To recover these 13 double homozygote females, tp53zdf1/zdf1;xrcc2+/- fish were 
incrossed (Fig. 2.4).  The xrcc2-/- genotype did not have a notably different male-to-
female sex ratio compared to xrcc2+/+ or xrcc2+/- in the tp53zdf1/zdf1 background (Fig. 2.4). 
 
Testicular germ cell tumors were observed in xrcc2 mutants 
As previously reported, brca2 mutant zebrafish develop testicular neoplasia, 
originating from somatic and germ cells 104.  Because of this, xrcc2 mutants were 
monitored for tumor development.  From 20-22.5 months (mo) of age, the xrcc2 mutants 





tumors by age 22.5 mo.  Seven out of 8 tumors were seminomas.  The other tumor was a 
disseminated round cell tumor, histologically most consistent with a lymphoma and 
present in tissues including the eye, gill, gut, gut mucosa, kidney, and liver (Fig. 2.5B).  
One seminoma was observed among 6 age-matched wild-type controls, and no 
seminomas were observed among the 4 age-matched xrcc2+/- controls. 
 
Mutant male gonads do not display other histologic changes 
 Gonad histology was examined for a total of 6 wild-type, 4 xrcc2+/-, and 16 xrcc-/- 
male zebrafish.  As previously mentioned, 6 of the xrcc2-/- and 1 wild-type male zebrafish 
had seminomas (Fig. 2.5B).  All 4 of the xrcc2+/- had normal spermatogenesis and orderly 
maturation (data not shown).  Of the 5 wild types that did not have a seminoma, 3 had 
normal spermatogenesis with orderly maturation (Fig. 2.6A). Two of the wild types had 
complete spermatogenesis with orderly maturation but possessed at least one small area 
of relatively increased spermatogonia (data not shown).  This small area of increased 
spermatogonia was also observed in 2 of the 10 xrcc2-/- males (data not shown).  One of 
the xrcc2-/- males showed testicular hypoplasia with arrested spermatogenesis (data not 
shown).  The remaining 7 xrcc2-/- males had normal spermatogenesis with orderly 
maturation (Fig. 2.6B).  Other than a relative increase in the incidence of seminoma in 
xrcc2-/- male zebrafish compared to xrcc2+/- and wild-type male zebrafish, there was no 








tp53zdf1/zdf1;xrcc2-/- females have normal oogenesis but 
defects in the liver 
The tp53-rescued xrcc2-/- females that do not possess tumors show complete 
oogenesis with orderly maturation of the oocytes (Fig. 2.7A).  The tp53zdf1/zdf1;xrcc2-/- 
females showed variable degrees of hepatocellular karyomegaly and binucleation (Fig. 
2.7B).  Of the 8 double-mutant females examined for histology, three had developed 
tumors (Fig. 2.7C and 2.7D).  Two of the tumors were spindle cell sarcomas, which are 
frequently observed in tp53-mutant zebrafish (Fig. 2.7C).  The third tumor was a 
hepatocellular carcinoma (HCC), a tumor not usually associated with tp53-mutation 
alone in zebrafish (Fig. 2.7D). 
 
Discussion 
We describe here the first viable vertebrate model of xrcc2 mutation.  XRCC2 was 
first discovered and cloned due to its ability to complement the DNA-repair defects seen 
in the irs1 Chinese hamster ovary (CHO) cell line, which has a point mutation causing 
aberrant splicing of the first intron 145–147.  Study of XRCC2 has remained limited by the 
lack of a vertebrate model; for example, mouse xrcc2-mutants are perinatal lethal due to 
failed neurogenesis 148. 
 
Zebrafish model supports xrcc2 as a Fanconi anemia gene 
All of the current evidence that XRCC2 is an FA gene comes from one human 
patient, who was homozygous for a p.Arg215* nonsense variant 51,52.  In this Saudi 





of FA cells, namely chromosome breakage, hypersensitivity to the interstrand 
crosslinking agent mitomycin C, and accumulation of cells in G2-M during the cell cycle 
51. These findings indicate the nonsense mutation in XRCC2 was the causative mutation 
in this patient 52. 
Three FA genes have been mutated in zebrafish: brca2, fancl, and rad51 resulting 
in mutant zebrafish that develop as males only 104,121,125.  Zebrafish sex determination is 
not as simple as the system used in mammals; it appears to be driven by genetic factors 
despite the lack sex chromosomes 127–129 (reviewed in Liew and Orbán 130).  Oocytes 
appear to be required to maintain a female phenotype, and loss of oocytes, even in adult 
zebrafish, leads to female-to-male sex reversal 132–134.  Rodriguez-Marí et al. 121 found in 
fancl mutants that there was increased germ cell apoptosis due to failure of oocytes to 
progress through meiosis.  A homozygous dominant-negative hypomorphic tp53M214K 
background decreased germ cell apoptosis rescued the male sex skew seen in brca2, 
fancl, and rad51 homozygotes 104,105,121,138,139.  Fance mutant mice show both primary 
ovarian insufficiency and delayed testicular germ cell maturation 122,149.  Similar to 
zebrafish, Fanca-/-; Fancg-/- double-mutant mice display defects in the ovaries with 
hyperplasia of interstitial cells and decreased follicle development 150. 
The xrcc2 mutants display a male sex skew caused by female-to-male sex 
reversal, which is consistent with results from brca2, fancl, and rad51 mutants 104,121,125.  
Also consistent with the other FA gene mutants, complementing xrcc2 with tp53M214K 
rescued the sex skew, and allowed us to recover viable, fertile females.  The xrcc2 mutant 
males developed seminomas at a frequency of 30.8% at 20-22.5 mo, which is consistent 





Gene expression in the gonads of wild-type and xrcc2-mutant zebrafish 
Because of the sex determination defect in xrcc2 mutants, we compared 
expression of several different genes, including xrcc2 and genes important for sex 
determination, in the gonads along with flank, gut, and head of wild-type and xrcc2 
mutants.  We found that xrcc2 is expressed at notably higher levels in testis and ovary 
than in other tissues in wild-type zebrafish.  This result, along with the sex skew, points 
towards an important role for xrcc2 in germ cell biology. 
In zebrafish, amh shows differential expression that is indicative of males, is 
restricted to the gonads, and is produced primarily by Sertoli cells 148,151,152.  In mammals, 
AMH represses formation of Muëllerian ducts in males, and it is involved in preventing 
primary ovarian insufficiency 68,153,154.  The function of amh differs slightly in zebrafish 
versus mammals because teleost fish lack Müllerian ducts 142,155,156.  We found that wild-
type testis had the highest amh expression, and wild-type ovaries had the lowest of the 
tissues examined.  The xrcc2 mutant testis fell in the middle, with significantly higher 
expression than the wild-type ovary and significantly lower expression than wild-type 
testis.  Female FA patients have been shown to exhibit less AMH in their serum, which 
may help explain the primary ovarian insufficiency often seen in these patients 68.  Fanc 
mRNAs may be enriched in mouse Sertoli cells, with FANCB, FANCM, and FANCI 
localizing to the nucleus and/or cytoplasm of Sertoli cells in mice 157. 
The zebrafish dmrt1 gene has three alternatively spliced isoforms, encoding 
proteins with varying lengths of 267, 246, or 132 amino acids, denoted a, b, and c 
respectively 143.  Dmrt1a is expressed at higher levels than the b and c isoforms 143.  





(Acanthopagrus schlegeli) fish species, with expression localized to Sertoli cells during 
development 158.  Expression of dmrt1 in Sertoli cells has also been reported in medaka, 
tilapia, and playfish 159–161.  In mice, Dmrt1 is required for testis differentiation and is 
expressed in Sertoli and germ cells 162.  Sertoli cell function is lost in Dmrt1-/- mice 162. 
Given the low levels of amh and moderate decrease in dmrt1a expression in 
xrcc2-/- testes, we hypothesized that there was a decrease in the number or function of 
Sertoli cells in xrcc2-/- fish.  We therefore decided to examine another Sertoli cell marker, 
igf3 144,163.  igf3 is expressed highly in the gonads with lower expression in other tissues 
like gills, and the igf3 gene is only present in teleost fish 163–165.  Given our hypothesis, 
we expected to find decreased igf3 expression in xrcc2-/- testis compared to wild type.  
Instead, we found that igf3 was moderately elevated in xrcc2-/- testes compared to wild 
type.  Indeed, Nóbrega et al. 163 reported that follicle-stimulating hormone (Fsh) promotes 
spermatogenesis through up-regulation of igf3 and repression of amh in zebrafish.  
Moreover, elevated FSH levels have been observed in FA patients 70.  The histologic 
findings did not show any defect in the number of Sertoli cells but also did not show 
consistent differences in spermatogenesis in the xrcc2-/- male zebrafish. 
These expression changes may play a role in the tumorigenesis that was observed 
in xrcc2 mutant testes.  In patients with seminomas, serum FSH levels were found to 
negatively correlate with spermatogenesis 166.  Elevated FSH levels were also found in 
seminoma patients compared to controls and nonseminoma germ cell tumors 167.  In 
humans, it is known that IGFs have antiapoptotic properties 168.  Additionally, IGFBPs, 
negative regulators of IGF signaling, are downregulated in seminomas 169.  Since it was 





the functional consequence of potentially elevated igf3 in xrcc2-mutant testis and if it 
contributes to the development of seminomas in these fish. 
 
The male sex skew is rescued by a tp53 mutation 
For the other known zebrafish FA gene mutants, crossing in the tp53 zdf1 allele, a 
missense substitution in the DNA binding domain, rescues the female-to-male sex skew 
104,105,121.  Despite the zdf1 allele being  dominant negative, previous studies found that 
only tp53zdf1/zdf1 could rescue the male sex skew 104,105,121.  For xrcc2, we found that the 
tp53-mutant background was sufficient to rescue xrcc2-/- females.  Since crossing the 
xrcc2 mutation into the tp53-mutant background rescues the sex skew in the xrcc2 
mutants, this finding illustrates that the mechanism for the sex switch in the xrcc2 
mutants is the same as in the brca2, fancl, and rad51 mutants. 
 
xrcc2 mutants develop testicular germ cell tumors 
In xrcc2 mutants, testicular germ cell tumors (TGCTs), all of which were 
seminomas, were observed beginning at roughly 20 months of age.  Human TGCTs have 
a 10-year survival rate of nearly 95% 170.  Standard treatment often involves platinum-
based chemotherapy agents (e.g., cisplatin), which is effective for most cases 170–172.  
Roughly 3% of tumors are cisplatin-refractory 172.  Patients with treatment-refractory 
tumors have a poor prognosis 173.  Litchfield et al. 172 reported whole exome sequencing 
from 2 treatment-refractory TGCTs and 41 nonresistant TGCTs.  xrcc2 mutations were 
present in both of the treatment-refractory TGCTs and none of the nonresistant TGCTs 





humans 174.  Testicular neoplasia, including both germ cell and somatic cell tumors, were 
also observed in the brca2 mutant zebrafish 104.  In this paper, we present the first 
seminoma model that is mutant for xrcc2. 
 
Gonad and germ cell development is normal prior to tumorigenesis in males 
 Despite promising qRT-PCR results, no consistent histologic differences were 
observed in the male gonads of the xrcc2 mutants compared to heterozygotes or wild 
types.  We therefore cannot explain the qRT-PCR results based on differences in the 
number of Sertoli cells or differences in spermatogenesis. 
 
Rescued female gonads and oocytes develop normally but there are liver 
abnormalities 
In the tp53zdf1/zdf1;xrcc2-/- females, oogenesis occurred normally, which is in 
contrast to tp53zdf1/zdf1;brca2Q658X/Q658X females that showed binucleated oocytes 104.  
Observation of 2 spindle cell sarcomas in the tp53zdf1/zdf1;xrcc2-/- females is not a 
surprising finding given that this tumor type is common in tp53-mutant zebrafish 138.  
However, HCC is not typically seen in tp53-mutant zebrafish lacking another mutation, 
but was observed when myca was overexpressed in the liver in a tp53-mutant background 
175.  Overexpression of HBx or src in the liver of tp53-mutant zebrafish also drives HCC 
formation 176.  Hepatocellular karyomegaly and binucleation were observed in the 
double-mutant females.  Traditionally, these liver phenotypes are thought to be related to 
toxicant exposure, but it has yet to be determined what the causative agent(s) is/are 177.  





the other zebrafish, there is a possibility that the tp53zdf1/zdf1; xrcc2-/- genotype contributes 
to the liver phenotypes.  Whole-exome sequencing of a hepatitis C virus-positive HCC 
revealed the presence of a missense substitution in XRCC2 (p.R91Q) 178.  Further 
research will be needed to determine what, if any, role xrcc2 mutations play in HCC and 
other liver pathology observed in the tp53zdf1/zdf1;xrcc2-/- females. 
 
Materials and methods 
Ethics statement 
All animals used in this study were used in accordance with the policies of the 




Zebrafish xrcc2 mutations were generated through transcription activator-like 
effector nuclease (TALEN) mutagenesis 114.  The xrcc2 TALEN recognition sequences 
were as follows: xrcc2 TALEN L: ACCACCTAATCACCCGCT xrcc2 TALEN R: 
CCAGACCTCCACTGT, and made by the Utah Mutation Generation and Detection core 
facility.  The tp53 mutant line used was the tp53zdf1 (amino acid change M214K) and was 
obtained from ZIRC (http://zebrafish.org/zirc/home/guide.php) 138.  Genotyping of tp53 
was carried out according to the protocol in 138.  Zebrafish were housed at the CZAR 







Genotyping of xrcc2 mutants 
Genotyping of xrcc2 mutants was carried out by polymerase chain reaction (PCR) 
and high-resolution melting curve analysis (HRMA) 179–181. Genomic DNA was isolated 
by alkaline lysis (incubation in 20-40 μl of 50 mM NaOH at 95 °C for 20 minutes, 
followed by addition of 2-4 μl of 1M Tris pH 8.0). Added to the PCR reaction for HRMA 
was LCGreen Plus+ Melting Dye [BioFire Defense BCHM-ASY-0005]. PCR conditions 
were: 2’ 95 °C; 42 cycles of 10” 95 °C, 15” 62 °C, 10” 72 °C; followed by 2’ 95 °C then 
hold at 12 °C. The PCR product size is 102 bp for WT, 94 bp for the 8-bp deletion 
mutant, and 92 bp for the 10-bp deletion mutant. The completed PCR reaction was then 
analyzed by HRMA with a temperature range of 70 °C to 95 °C on a LightScanner HR I 
96 [Idaho Technology Inc.] using small amplicon-based genotyping for melting curve 
data analysis. 
 
RNA isolation and qRT-PCR 
Dissected tissues were briefly washed in 1X phosphate buffered saline (PBS) pH 
7.4 and placed in 600 µl of TRIzol® Reagent (Thermo Fisher Scientific 15596026). The 
following tissues were used: flank (posterior of the anal fin), gut, head (anterior of the gill 
slit), ovary, and testis. Tissues from four different fish were pooled for each sample. 
Tissues were homogenized using a Kontes Pellet Pestle Motor.  Purified RNA was 
isolated using the Direct-zol™ RNA MiniPrep Plus (Zymo Research R2072) according 
to the manufacturer’s protocol, including the DNase I treatment step.  RNA concentration 
and quality was assessed using a NanoDrop, ND-1000 Spectrophotometer.  1 µg of 
DNase I-treated RNA was reverse transcribed with random hexamer primers to produce 
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cDNA using the SuperScript® III First-Strand Synthesis System (Thermo Fisher 
Scientific 18080051) according to the manufacturer’s protocol. Quantitative reverse 
transcription PCR (qRT-PCR) was carried out using PowerUp™ SYBR™ Green Master 
Mix (Thermo Fisher Scientific A25742) for the following genes: b-actin, amh, dmrt1a, 
igf3, and xrcc2 141,164,182,183.  Expression was calculated using 2-ΔΔCT and normalized to b-
actin. 
Tumor isolation 
Zebrafish aged 20-22.5-months post fertilization (mpf) were fixed in 4% 
paraformaldehyde (PFA) for one week at 4 °C.  The fish were removed from the 4% PFA 
and washed twice in 1X PBS pH 7.4.  The fish were then placed in 0.5M 
ethylenediaminetetraacetic acid (EDTA) pH 8.0 for one week at room temperature.  Fish 
were then bisected along the sagittal plane.  Research Histology at the Huntsman Cancer 
Institute (Salt Lake City, UT) performed paraffin embedding, para-sagittal sectioning 
with cut-side up, and stained with hematoxylin and eosin. Tumors were evaluated by two 
pathologists (HRS and KJE). 
Gonad histology 
The slides for gonad histology were prepared as described above for tumor 
isolation utilizing 20-22.5 mpf wild-type, xrcc2+/-, and xrcc2-/- male zebrafish or 12 mpf 
tp53zdf1/zdf1; xrcc2-/- females. Gonad histology was evaluated by a veterinary pathologist 
(HRS). 
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Figure 2.1. TALEN-induced frameshift mutation in zebrafish xrcc2.  (A) Zebrafish xrcc2 
gene structure showing the TALEN cut site in the third and final exon. F and R indicate 
the forward and reverse primers for genotyping and qRT-PCR of xrcc2.  Two xrcc2 
mutant alleles were generated, an 8-base-pair (bp) and 10-bp deletion with the resulting 
amino acid changes that occur in each mutation in exon 3.  Both result in a frameshift that 
disrupts most of the P-loop NTPase domain, without causing nonsense mediated decay. 
HRM genotyping curves of a wild-type, heterozygote, and homozygote for the xrcc2 8-bp 





Figure 2.2. xrcc2 mutants are all male due to female-to-male sex reversal and not female 
lethality.  (A) The bars represent the number of fish that are male (lines) or female (dots) 
for wild-type, heterozygote, and homozygote xrcc2 genotypes.  Within the xrcc2-/- 
genotype, only males are observed, while normal sex ratios were seen for wild types and 
heterozygotes.  (B) The bars represent the number of fish that are male (lines) or female 
(dots) for wild type, heterozygote, and homozygote xrcc2 genotypes, with solid grey bars 
representing expected numbers for each genotype and gender.  For a homozygote crossed 
to a heterozygote, the expected number of heterozygous progeny equals the expected 
number of homozygous progeny.  Because that is the case for xrcc2 with 112 
homozygous progeny to 108 heterozygous progeny, we conclude that all homozygotes 






Figure 2.3. xrcc2-mutant testes show aberrant gene expression compared to wild-type 
testes.  (A) qRT-PCR expression of xrcc2 in wild-type testis, ovary, flank (posterior of the anal 
fin), gut, head (anterior of the gill slit) and xrcc2 mutant testis, flank, gut, and head.  There was 
98-fold higher expression (p<0.05) of xrcc2 in wild-type testes and 75-fold higher expression 
(p<0.05) in wild-type ovaries compared to wild-type flank, gut, and head.  Since the xrcc2 
mutation is in the final exon, the mRNA should not be subjected to nonsense mediated decay.  
There was no significant difference (p>0.05) in xrcc2 expression in wild-type flank, gut, or head, 
and xrcc2 flank, gut, or head, which suggests the transcript is not degraded.  However, the xrcc2 
testes showed 3-fold less xrcc2 expression (p<0.05) compared to wild-type testes.  (B) amh is 
expressed 3-fold higher (p<0.05) in wild-type testis compared to xrcc2 testis and 64-fold higher 
(p<0.05) than in wild-type ovaries. amh is expressed 20-fold higher (p<0.05) in xrcc2 testis 
compared to wild-type ovaries.  (C) 1.5-fold increased igf3 expression in the xrcc2-mutant testes 
compared to wild-type testes is trending towards significance (p=0.21).  igf3 is expressed 4-fold 
higher (p<0.05) in xrcc2-mutant testes and 2.8-fold (p=0.12) in wild-type testes compared to 
wild-type ovaries.  (D) 1.2-fold decreased dmrt1a in the xrcc2 mutant testes compared to wild-
type testes is trending towards significance (p=0.20).  Wild-type testes had 508-fold higher 
expression (p<0.05) of dmrt1a than wild-type ovaries and xrcc2-mutant testes had 96-fold higher 












Figure 2.4. tp53 mutations rescue the female-to-male sex reversal in xrcc2 mutants. The 
bars represent the number of fish that are male (lines) or female (dots) for wild-type, 
heterozygote, and homozygote xrcc2 genotypes in a tp53-mutant background.  The 
mutant tp53 allele used was zdf1, which is a dominant-negative missense substitution in 









Figure 2.5. xrcc2-mutant males develop seminomas. At roughly 20 mo, xrcc2 mutant 
males show seminomas.  (A) Seminoma in an age-matched wild-type control and a 
representative seminoma from an xrcc2 mutant male.  (B) Disseminated round cell tumor, 
with morphologic features suggestive of lymphoma, present in the eye, gill, gut, gut wall, 






Figure 2.6. xrcc2-mutant male testes are histologically normal. Complete 
spermatogenesis with orderly maturation occurs in the majority of wild-type (A) and 







Figure 2.7. tp53;xrcc2 double-mutant females have normal oogenesis but liver defects. 
(A) Complete oogenesis with orderly maturation of oocytes with all stages present occurs 
in the tp53zdf1/zdf1;xrcc2-/- females.  (B) Hepatocellular karyomegaly and binucleation 
present in the livers of tp53zdf1/zdf1;xrcc2-/- females.  (C) Spindle cell sarcoma in a 














ZEBRAFISH RAD50 MUTANTS HAVE A GROWTH DEFECT, HEMATOPOIETIC 
DEFECTS, AND RADIOSENSITIVITY 
 
Abstract 
RAD50 encodes a key protein in the DNA double-strand break (DSB) repair 
pathway, functioning in both the nonhomologous end-joining and homology-directed 
DSB repair pathways as part of the MRN complex with Mre11 and Nibrin.  Biallelic 
mutation of NBN results in the disease Nijmegen breakage syndrome (NBS), and biallelic 
hypomorphic mutations in RAD50 result in the clinically similar NBS-like disease.  
Because of its importance in early development, no vertebrate model for a null mutation 
in RAD50 exists that allows for study in later development.  We report here the first 
viable rad50 null mutant using zebrafish.  We found that rad50-mutant zebrafish share 
many clinical features with human NBS patients.  These fish show decreased size, 
increased sensitivity to ionizing radiation, and hematopoietic defects. 
 
Introduction 
RAD50 encodes one of three proteins, along with MRE11 and NBN, composing 
the MRN complex, which is a heterohexamer composed of dimers of each of these three 





screen for genes involved in DNA repair in Saccharomyces cerevisiae 185.  Each Rad50 
protein binds an Mre11 protein and dimers of these form the “core” complex of the MRN 
complex 184.  Rad50, as part of the MRN complex, binds DNA using its N-terminal 
Walker A motif and C-terminal Walker B motif that bind each other to form an ATP-
binding cassette (ABC)-type ATPase domain 14,186.  Nibrin functions to help with 
downstream signaling and proper localization of the MRN complex and interacts with the 
Rad50 flexible adapter 9,11,16–18.  The MRN complex associates with damaged DNA ends, 
playing a role in both DNA double-strand break repair and in recognizing exogenous 
viral DNA and limiting viral replication 184,187–190.  There are two main mechanisms for 
repair of DNA double-strand breaks (DSBs): nonhomologous end-joining (NHEJ) and 
homology-directed DSB repair (HDR) 3–5.  The MRN complex acts early enough in the 
DSB repair pathway that it promotes both NHEJ and HDR 191.  Like many DSB repair 
genes, all three genes in the MRN complex are either known or candidate moderate risk 
breast cancer susceptibility genes 96,192–194. 
Ataxia-telangiectasia mutated (ATM) is an important downstream target of the 
MRN complex. ATM is a serine-threonine kinase that phosphorylates many different 
targets, including 53BP1, Chk1, Chk2, H2AX, KAP-1, p53, and SMC1 among others 195–
201.  The MRN complex plays a role in ATM phosphorylation of targets Chk1, Chk2, and 
p53; however, there is no reduction in phosphorylation of histone H2AX with the loss of 
an MRN component 202–207.  Phosphorylated histone H2AX, which is called gH2AX, is an 
important signal for DNA damage repair 21,22.  In addition, ATM phosphorylates Nibrin, a 
step that is required for intra-S-phase checkpoint activation 208–211. 





telangiectasia (A-T) 71.  Patients carrying two MRE11 mutations get the related disease 
ataxia-telangiectasia-like disorder (ATLD) 72.  Biallelic NBN mutations result in the 
disease Nijmegen breakage syndrome (NBS) 61,62.  While they are all distinct diseases, A-
T, ATLD, and NBS all share some key features including cellular phenotypes and 
chromosomal abnormalities 61,73.  One main difference between A-T and NBS is that A-T 
patients suffer from cerebellar degeneration while this is not present in NBS patients 
61,62,71,73.  While there are immunological deficiencies observed in A-T patients, they are 
due to errors in V(D)J recombination 212–214.  Hematopoietic failure is not observed in A-
T patients, but it has been seen in NBS patients.  A Japanese child with NBS presented 
with aplastic anemia, and two unrelated Russians with NBS presented with bone marrow 
aplasia in a study conducted on eight individuals 54,55.  One of the Russian patients also 
presented with acute myeloid leukemia (AML); coupling the finding of AML with the 
bone marrow failure illustrates key similarities of NBS to another disease caused by 
inherited mutations in DNA repair genes: Fanconi anemia 54.  Other clinical features of 
NBS include chromosomal instability, growth retardation, microcephaly, and 
radiosensitivity 61,62.  In addition to AML, non-Hodgkin lymphoma has been reported in 
children with NBS 215. 
In 1991, a four-year-old German patient presented with symptoms consistent with 
NBS 75.  The patient did not carry two mutations in the NBN gene; however, the patient 
did carry two different mutations in RAD50, a nonsense mutation (c.3277C→T; 
p.R1093X) and a mutation that removed the stop codon (c.3939A→T) 50.  The loss of the 
stop codon mutation is predicted to add 66 additional amino acids (p.X1313YextX*66) 





conserved at the C-terminus as determined from a protein multiple sequence alignment 
from humans through Danio rerio, illustrating why this mutation adding 66 amino acids 
is likely so damaging to Rad50 function 96.  This patient was found to have less than 5% 
of the Rad50 protein level compared to wild type 50.  Based on results from this human 
patient, biallelic RAD50 mutations result in an NBS-like disease phenotype. 
 Rad50-null mice are not viable 74.  However, three different viable point 
mutations have been created in Rad50 in mice; Rad50S (K22M), which is a point 
mutation in the Walker A motif, and two Rad50 hook domain mutant, the Rad5046 and 
Rad5047 alleles, which are analogs to the yeast rad50-46 and rad50-47 alleles, which 
modify how the Zn2+ ion interacts with the Rad50 hook domain 76,77,216,217.  In the 
Rad50S/S mutants, the mice are decreased in size and die of hematopoietic failure 
beginning at 4-8 weeks of age 76,77.  These phenotypes can be rescued by mutating p53, 
but the double mutants then die instead of cancer faster than p53-/- alone from tumors that 
fall within p53-/- tumor spectrum 76,77,218. 
 
Results 
rad50 mutants are juvenile lethal and show a significant growth reduction 
The role that rad50 plays in zebrafish development was investigated through 
mutant generation using a transcription activator-like effector nuclease (TALEN).  The 
TALEN was targeted to exon 3, disrupting the ATPase-N domain and creating a 
premature stop codon.  A 7-base-pair (bp) frameshift mutation was recovered from the 
TALEN mutagenesis (Fig. 3.1A).  Genotyping of the rad50 7-bp deletion was performed 





After the rad50 mutants were generated with TALENs, the rad50+/- fish were 
incrossed to determine if the rad50-/- zebrafish are viable.  We found that at 17 days 
postfertilization (dpf), we were able to recover wild-type, rad50+/-, and rad50-/- zebrafish 
in Mendelian ratios (Fig 3.2A).  However, at 9 weeks postfertilization (wpf), we failed to 
recover any rad50-/- zebrafish (Fig. 3.2B).  The rad50-/- zebrafish were still viable at 6 
wpf, but they showed a significant size reduction (Fig. 3.2C, 3.2D, and 3.2E).  The 
average length for the 6 wpf rad50-/- zebrafish was 1.61 cm, which was significantly 
smaller than the 2.51 cm length (N=25) for the wild-type and heterozygous siblings (Fig. 
3.2D and 3.2E).  The 6 wpf rad50-/- zebrafish had a mass of 26.83 mg (N=15) on average 
compared to significantly greater mass of 104.76 mg (N=25) for the wild-type and 
heterozygous siblings (Fig. 3.2E). 
 
rad50 mutants are radiosensitive 
Given the role rad50 plays in DNA repair, we tested to see if our mutants were 
radiosensitive. 3 wpf rad50+/- incross fish were irradiated with 0, 20, or 40 Gy of ionizing 
X-ray radiation and then monitored for survival over the course of three weeks.  The 
unirradiated group survived for the entire three-week period (data not shown).  At 20 Gy, 
rad50-/- zebrafish all perished by 9 days postirradiation (dpi) while roughly 70% of the 
wild-types and heterozygotes survived the three-week time period (Fig. 3.3A).  At 40 Gy, 
rad50-/- zebrafish all perished by 7 dpi while wild-types and heterozygotes perished by 13 
dpi (Fig. 3.3B). 
Since loss of rad50 does not decrease gH2AX, a western blot was performed for 





and rad50-/- zebrafish.  Samples were collected 5 hours, 24 hours, or 48 hours 
postirradiation (hpi).  The rad50-/- samples showed gH2AX staining at each time point, 
while the wild-type and rad50+/- samples showed lower staining at each time point 
compared to the mutants (Fig. 3.3C).  It was further determined that in wild-type 
zebrafish, gH2AX shows strongest staining at 3 hpi and then decreases over time, 
completely disappearing by 18 hpi (Fig. 3.3D).  Repeating the experiment with 5 dpi 
wild-type and rad50-/- zebrafish, again irradiating with 15 Gy but collecting samples at 18 
hpi, there was strong staining of gH2AX for the rad50-/- sample but none for the wild-
type sample (Fig. 3.3E).   
 
rad50 mutants have leukocytopenia starting at 3 wpf 
Using whole-mount RNA in situ hybridization (WISH) for hematopoietic stem 
cell (HSC) markers cmyb and runx1, we found that the rad50-/- mutants did not have any 
defect in the emergence of HSCs (Fig. 3.4A).  No defect was observed in migration or 
colonization of adult HSC niche in the kidney or thymus in the rad50-/- mutants using 
cmyb and rag1 as markers for WISH (Fig.3. 4B).  While there were no defects in the 
emergence of colonization of HSCs, there was a defect in the hematopoietic system of the 
rad50-/- zebrafish at 3 wpf.  The fish showed a marked reduction in the number of pan-
leukocytes compared to wild-type and heterozygous siblings (Fig. 3.4C).  This was 
determined through whole-mount immunofluorescence with an antibody against 
zebrafish L-plastin, a pan-leukocyte marker and using confocal microscopy examining 







The rad50-/- zebrafish are the first viable vertebrate model for a null rad50 
mutation.  Rad50, a member of the MRN complex, is conserved in archaea like 
Pyrococcus furiosus and has an ortholog present in prokaryotes called SbcC 219,220.  
Rad50-mutant mice are embryonic lethal, with the embryos appearing smaller and being 
reabsorbed starting at E6.0 through E8.5 74.  In zebrafish, rad50 is maternally provided; 
we verified this via quantitative real-time PCR (data not shown).  Given that Rad50-
mutant mice fail early in development, we hypothesize that the only reason the rad50-/- 
zebrafish are viable is due to maternal effect because the maternal supply of rad50 is 
present during early embryonic development.  We were not able to generate a maternal-
zygotic null for rad50 and did not find any mutant phenotypes prior to 5 dpf. 
The maternal effect for rad50 was a bit of a double-edged sword for us.  While it 
likely is what allowed us to recover viable rad50 mutants, it made study of the early 
development effects of rad50 in zebrafish impossible.  Because rad50 mutants never 
reached breeding size, and the attempts we made to breed them were all unsuccessful, we 
could not use rad50-/- females to bypass maternal effect.  We explored several transgenic 
approaches to bypass maternal effect.  We put rad50 under the control of two different 
promoters that do not have maternal effect, heat shock protein 70 and ubiquitin.  
However, neither of these promoters allowed us to recover normal-sized rad50 mutants.  
We also attempted gene targeting to generate a floxed rad50 allele, but this technology is 
still in its infancy in zebrafish, and we failed to recover any zebrafish with successfully 






rad50 mutants are radiosensitive 
Both human and mouse cells that are mutant for Rad50 are radiosensitive 74,221.  
rad50-mutant zebrafish are also radiosensitive by irradiating 3 wpf rad50+/- incross fish 
with two doses of radiation: 20 and 40 Gy.  We found that the rad50-/- fish died 
significantly earlier than the wild-type and heterozygous siblings.  We also found that 
rad50-/- zebrafish showed more gH2AX staining following irradiation and showed 
staining for longer.  gH2AX, phosphorylated histone H2AX, is a marker of DNA damage 
222.  Histone H2AX is phosphorylated by ATM 222.  In two different rad50 mouse 
mutants, the Rad50S allele and a hook domain mutation, Rad5046, ATM is overactivated 
77,217.  Further, mutating ATM in these Rad50-mutant backgrounds results in a less severe 
phenotype than in either Rad50 mutation alone 77,217.  Further, it has been shown that 
Rad50 is phosphorylated by ATM, an event that regulates both the cell cycle and DNA 
repair, further illustrating the key interactions between these two proteins 223.  
Since histone H2AX is phosphorylated by ATM kinase, there are two alternative 
hypotheses to explain the increased gH2AX seen in the rad50 mutants: increased DNA 
damage or overactivation of ATM.  There is constitutive gH2AX in the Rad50 hook 
domain mouse mutants Rad50+/46 and Rad50+/47 217.  Phosphorylation of gH2AX was also 
observed in the absence of irradiation in the Rad50S/S mice 77. 
ATM is constitutively expressed and is not up-regulated in response to DNA 
damage 224.  Instead, ATM is regulated posttranslationally via autophosphorylation at 
serine 1981, which is considered a marker for ATM activation 225.  This means that to 
monitor ATM activation, an antibody against the phosphorylated form is required.  This 





was increased activation of ATM in our rad50-/- zebrafish. 
 
Unlike in mice, mutating tp53 does not rescue the rad50-mutant zebrafish 
In the Rad50S/S mice, mutating tp53 provided a partial rescue to the hematopoietic 
failure and size defect 76.  However, crossing our rad50 mutants into a tp53zdf1/zdf1-mutant 
background failed to rescue the defects seen in the rad50-/- zebrafish (data not shown).  
We have found that tp53zdf1/zdf1-mutant background does rescue the sex determination 
defect we see in our xrcc2-/- mutants (manuscript submitted).  It is possible that the 
tp53zdf1/zdf1-mutant background fails to rescue our rad50-/- zebrafish while it does rescue 
the Rad50S/S mice because the zebrafish rad50 mutation is a null while the Rad50S allele 
is not.  It could also stem from the differences in hematopoiesis in mammals compared to 
fish.  The hematopoietic stem cells develop in the bone marrow in mammals (and all 
terrestrial vertebrates), while they reside in the kidney in zebrafish. 
 
The rad50 mutants have hematopoietic defects 
There were no defects with HSC emergence or colonization of the thymus or 
kidney, the adult niches in zebrafish.  These results are not surprising given the fact that 
both of these events occur early enough in development that maternal effect is still likely 
occurring for rad50.  We did not observe a phenotype for the hematopoietic system until 
3 wpf at which point we observed a significant decrease in the number of leukocytes.  We 
did not perform IHC to look for defects in the HSC population at 3 wpf.  We hypothesize 
what is occurring is an accumulation of DNA damage in the rapidly dividing HSCs that 





factor in rad50.  In both the Rad50S and Rad5046 hypomorphic Rad50 mouse mutants, 
there are defects in the primitive hematopoietic cells and germ cells 76,77,217.  The stem 
cells from Rad50S mutants cannot reconstitute the bone marrow in lethally irradiated 
wild-type mice 77.  There is also evidence that ATM activation may play a role in anemia.  
ATM activation has been implicated in Diamond-Blackfan Anemia (DBA) in zebrafish 
226.  DBA is an anemia caused by impaired RNA processing due to a deficiency in 
ribosomal proteins and involves the DNA damage repair pathway 226,227.  Since we 
hypothesize there is overactivation of ATM in our rad50 mutants based on results from 
two mouse Rad50 mutants, this may be contributing to the hematopoietic defects that we 
are seeing. 
To determine if the rad50-mutant size defect was due to hematopoietic failure, we 
attempted to rescue the rad50-/- fish by performing an HSC transplant experiment.  It has 
been shown that HSC transplant allows lethally irradiated fish to survive hematopoietic 
failure 228.  However, we were unable to successfully rescue with an HSC transplant.  It is 
not clear if this was due to technical failures due to the complicated nature of the 
experiment, or if the transplant does not rescue.  It did not appear that the transplanted 
HSCs colonized the kidney in the rad50 mutants (data not shown).  This would suggest a 
technical failure, and it may be worth repeating this experiment in the future.  If we are 
able to successfully perform an HSC transplant experiment, it will offer insight into the 
mechanism for the small size of the rad50 mutants.  The fish would be rad50-/- in every 
cell type except for in the hematopoietic system, so if they reach a normal size, it would 
suggest that the hematopoietic defects were the cause of the small size.  However, if they 





apoptosis or decreased cellular proliferation. 
 
First viable model of a null mutation in rad50 in a vertebrate 
We were able to generate the first viable vertebrate model of homozygous rad50 
null mutation.  In our model, we were able to recapitulate some clinical features seen in 
NBS, namely decreased size, radiosensistivity, and hematopoietic failure.  Given the 
similarities between ATM, MRE11, NBN, and RAD50 mutant phenotypes, zebrafish may 
prove to be a great model system to study mutations in those other genes as well. 
While we were able to learn some roles for rad50 in zebrafish from our mutants, 
technical challenges associated with these mutants stemming from maternal effect, 
difficult experiment techniques, and lack of key reagents have left many open questions 
about the mechanism for the effects of the rad50-mutant phenotype we observed. 
 
Materials and methods 
Ethics statement 
All animals used in this study were used in accordance with the policies of the 




Transcription activator-like effector nuclease (TALEN) mutagenesis was 
performed to generate the rad50 zebrafish mutants 114.  The rad50 TALENs were 





recognition sequences: rad50 TALEN L: ACATCACATCAGGAGACT rad50 TALEN 
R: GGACAAAAGTGTTTCCTTT.  Zebrafish were housed at the CZAR (Centralized 
Zebrafish Animal Resource) facility at the University of Utah. 
 
Genotyping of rad50 mutants 
rad50 mutants were genotyped using polymerase chain reaction (PCR) and high-
resolution melting curve analysis (HRMA) 179–181.  Isolation of genomic DNA was 
carried out by alkaline lysis (incubation in 20-40 µl of 50 mM NaOH at 95 °C for 20 
minutes, followed by addition of 2-4 µl of 1M Tris pH 8.0).  PCR primers were as 
follows: rad50 F TTTTTGCAGACCATCATTGAG and rad50 R 
TCAATGACTTACTTTGGGATCA. LCGreen Plus+ Melting Dye [BioFire Defense 
BCHM-ASY-0005] was added to the PCR reaction to perform HRMA.  PCR conditions 
were: 2’ 95 °C; 45 cycles of 10” 95 °C, 15” 62 °C, 10” 72 °C; followed by 2’ 95 °C then 
hold at 12 °C.  The PCR product size is 105 bp for wild-type and 98 bp for the 7-bp 
deletion mutant.  HRMA was used to analyze the completed PCR reaction with a 
temperature range of 70 °C to 95 °C on a LightScanner HR I 96 [Idaho Technology Inc.] 
using small amplicon-based genotyping for melting curve data analysis. 
 
Radiation survival 
rad50+/- were incrossed and 3 wpf fish were irradiated with 0, 20, or 40 Gy using 
ionizing X-ray radiation.  The fish were separated based on radiation dose and not by 
genotype.  The irradiated and unirradiated fish monitored for survival over the course of 





lights went out at 11 p.m.  Dead fish were made into DNA and genotyped following the 
protocol previously described above. 
 
Western blot analysis 
To detect gH2AX, a western blot was performed for gH2AX was performed with 
GAPDH used as the loading control.  7 dpf wild-type, rad50+/-, and rad50-/- zebrafish 
were irradiated with 15 Gy of ionizing X-rays.  Irradiated zebrafish embryos were 
collected 5 hours, 24 hours, and 48 hours postirradiation (hpi).  Each embryo needed to 
be genotyped, so the tail was made into DNA and genotyped following the above 
protocol. The rest of the embryo was placed into complete radioimmunoprecipitation 
assay (RIPA) buffer (1% Nonide P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate) containing 1% protease inhibitors (Sigma P8340) and 1% benzonase (Novagen 
70746-3) and were homogenized using a Kontes Pellet Pestle Motor.  Protein 
concentrations were determined by the BCA assay kit (Thermo Scientific 23227).  The 
western blot used precast denaturing gels (Novex NP0301BOX) and 25 µg of protein was 
loaded.  A prehydrated PVDF membrane (GE PV4HYA0010) was used for the transfer.  
The membrane was blocked with 3% bovine serum albumin (Amresco 0332) in 1X tris-
buffered saline with 1% tween-20 (TBST).  The blot was stained with anti-Phospho-
Histone H2A.X (Ser139) at 1:2,000 and anti-GAPDH antibody (Abcam 9484) at 1:2,000 
in block and incubated overnight at 4 °C.  Washes were carried out in 1x TBST four 
times for five minutes each.  For anti-Phospho-Histone H2A.X (Ser139), anti-rabbit-
horseradish peroxidase secondary (Cell Signaling 7074S) was used, and for anti-GAPDH, 





secondary antibody was used at 1:5000 in the same block used for the primary antibodies.  
The secondary antibodies were incubated at room temperature for 30 minutes.  The blot 
was washed five times for 10 minutes each in 1x TBST.  Following washing, the blot was 
treated with chemiluminescent horseradish peroxidase substrate (Millipore WBKLS0500) 
and exposed to film (ThermoFisher Scientific 34090) to detect protein signal. 
 
Whole-mount RNA in situ hybridization (WISH) 
 Previously described protocols were followed for WISH 229,230. 
 
Whole-mount immunofluorescence 
Using rad50+/- embryos at 2 and 3 weeks postfertilization, whole-mount 
immunofluorescence was performed following previously described protocols using an 
anti-L-plastin antibody at 1:10,000 dilution followed by the secondary antibody Alexa 







Figure 3.1. TALEN-induced frameshift mutation in zebrafish rad50. (A) Zebrafish rad50 
gene structure showing the TALEN cut site in the third exon disrupting the ATPase-N 
domain. Genotyping primers for rad50 labeled F and R indicate the forward and reverse 
primers.  A 7-base-pair (bp) deletion in rad50 was generated through TALEN 
mutagenesis with the resulting amino acid changes that occur in exons 3 and 4 including 
the premature stop codon.  (B) HRM genotyping curves of a wild-type, heterozygote, and 







Figure 3.2. rad50 mutants are juvenile lethal with a growth defect.  Genotyping was 
performed via HRM with grey representing wild types, red for rad50+/-, and blue for 
rad50-/-. (A) Mendelian ratios were recovered wild type, rad50+/-, and rad50-/- zebrafish 
from a rad50+/- incross at 17 days postfertilization (dpf).  (B) No rad50-/- zebrafish 
survived to 9 weeks postfertilization (wpf) out of 20 rad50+/- incross progeny.  (C) At 6 
wpf, a normal Mendelian ratio was recovered with 7 rad50-/- zebrafish out of 27 rad50+/- 
incross progeny.  6 wpf rad50-/- zebrafish are significantly smaller than wild-type and 
rad50+/- siblings for both length and mass representative images in (D) and quantification 










Figure 3.3. rad50-/- zebrafish are radiosensitive.  rad50-/- zebrafish die significantly 
faster than wild-type or rad50+/- siblings when exposed to 20 Gy (A) or 40 Gy (B) of 
ionizing X-ray irradiation.  (C) 7 dpf wild-type, rad50+/-, and rad50-/- zebrafish were 
irradiated with 15 Gy of ionizing X-rays, and a western blot was performed for gH2AX 
with samples collected 5, 24, and 48 hours postirradiation (hpi).  GAPDH was used as the 
loading control.  rad50-/- zebrafish showed elevated levels of gH2AX at each time point 
compared to wild-type and rad50+/- siblings.   (D) 6 dpf wild-type zebrafish were 
irradiated with 15 Gy of ionizing X-rays, and a western blot was performed for gH2AX 
with samples collected 3, 6, 12, 18, and 24 hpi with an unirradiated control.  GAPDH was 
used as the loading control.  The wild-type zebrafish cleared gH2AX by 18 hpi.  (E) At 
18 hpi, 5 dpf rad50-/- zebrafish have elevated gH2AX compared to wild-type siblings 









Figure 3.4. Leukocytopenia occurs in rad50-/- beginning at 3 wpf.  (A) Whole-mount 
RNA in situ hybridization (WISH) was performed using the hematopoietic stem cell 
(HSC) markers cmyb and runx1 on 28 to 32 hour postfertilization rad50+/- incross 
embryos.  Blue arrows point to HSCs.  There was no defect in the emergence of HSCs in 
rad50-/- embryos.  (B) 5 dpf rad50+/- incross embryos were analyzed for proper HSC 
migration to the adult niches in the kidney and thymus using WISH for cmyb and rag1.  
Blue arrows point to the thymus, and green arrows point to the kidney.  39/41 embryos 
had proper migration to the kidney and thymus using cymb, and 43/43 embryos had 
proper migration to the thymus using rag1.  (C) Whole-mount immunofluorescence using 
an antibody against zebrafish L-plastin, a pan-leukocyte marker, was performed with a 
confocal microscope examining the tails of 3 wpf rad50+/- incross zebrafish.  rad50-/- 














Zebrafish  (Danio rerio) have traditionally been used for developmental studies 
because transparent embryos and external fertilization allow easier study of early steps in 
development compared to mammalian systems 233.  Zebrafish have also been used for 
many forward genetic screens 234–237.  With the development of transcription activator-
like effector nucleases (TALENs) and CRISPR/Cas9, it is now possible to make targeted 
mutations and perform reverse genetics in zebrafish, allowing the study of specific genes 
114,238–240.  With the advances in reverse genetics techniques available in fish, zebrafish 
were selected as the model organism to study several strong candidate moderate risk 
breast cancer susceptibility genes: RAD50 and XRCC2. 
RAD50 and XRCC2 play important roles in DNA double-strand break (DSB) 
repair 3–5.  Rad50 functions early in the pathway in a complex with Mre11 and Nibrin 7,8.  
XRCC2 is a Rad51 paralog that acts specifically in the homology-directed DSB repair 
(HDR) pathway 38.  In addition to playing a role in DNA DSB repair and breast cancer 
susceptibility, biallelic mutations in RAD50 result in Nijmegen breakage syndrome-like 
disorder, a disorder similar to Nijmegen breakage syndrome (NBS), while biallelic 
mutations in XRCC2 result in Fanconi anemia (FA) 50–52.  While they are different 





(AML), bone marrow failure, thumb defects, microcephaly, and growth retardation 53–
55,57–67,143,241.  Additionally, there are no viable mouse models that possess bialleic null 
mutations in either RAD50 or XRCC2 74,148. 
Most of what is known about biallelic null mutations in XRCC2 comes from the 
Chinese hamster ovary cell line irs1 43,49,118,242.  A patient homozygous for p.Arg215* 
nonsense mutation in XRCC2 had FA 51,52.  There have been multiple studies on Rad50 in 
mice using missense substitutions that are not null alleles 77,217.  The patient who had 
NBSLD carried two different RAD50 alleles, a nonsense mutation (c.3277C→T; 
p.R1093X) and a lost stop codon mutation (c.3939A→T) that added 66 amino acids to 
the C-terminus 50.  This patient presented with a Rad50 protein level that is 95% less than 
a wild-type person 50. 
 
Zebrafish models of rad50 and xrcc2 mutations 
Since there are no viable mouse models for biallelic null alleles for either gene, 
zebrafish were chosen as the model system to study the effects that mutations in rad50 
and xrcc2 play in later vertebrate development.   In zebrafish, other HDR pathway genes 
such as BRCA2 for which homozygous null mutations result in embryonic lethality in 
mice, are viable 104,105,243. 
 
rad50 mutants show growth retardation, hematopoietic defects, 
and radiosensitivity 
The rad50 mutants showed growth retardation beginning at 3 weeks 





heterozygous siblings.  Also at 3 wpf, the rad50-/- zebrafish showed leukocytopenia.  This 
was determined using an antibody against the pan-leukocytes marker L-plastin and 
performing fluorescent microscopy to examine leukocytes in the tails of 3 wpf wild-type 
or rad50-/- zebrafish.  We hypothesized that hematopoietic stem cell (HSC) failure was 
the cause of the leukocytopenia since HSC failure has been observed in human NBS and 
NBS-like disorder patients and mouse Rad50S/S mutants 50,53,76.  There were no defects in 
the emergence of the HSCs or colonization of the adult niches in the kidney or thymus.  
While the leukocytopenia was never rescued, the growth retardation was likely due to the 
hematopoietic system defects. 
To attempt to rescue the leukocytopenia and possibly size defect, a HSC 
transplant experiment was attempted.  The transplant experiment failed to rescue the 
rad50-/- growth defect or leukocytopenia.  Since these experiments are technically 
challenging, it bears repeating to determine if the first experiment was a technical failure 
or if an HSC transplant is not sufficient to rescue the rad50-/- growth retardation.  
Another possible experiment would be to express rad50 under the control of the CD41 
promoter, which is expressed in HSCs 244. 
rad50 is an important DNA repair factor, and the rad50-/- zebrafish showed DNA 
repair defects.  When irradiated with 15 Gy of ionizing radiation, the rad50-/- zebrafish 
failed to clear gH2AX, a marker of DNA damage, compared to wild-type and rad50+/- 
zebrafish.  When 3 wpf rad50-/- incross fish were irradiated with 20 or 40 Gy, the rad50-/- 
fish died significantly earlier than wild-type and heterozygous siblings. 
One possible alternative explanation for the elevated gH2AX is that ATM has 





is the kinase responsible for phosphorylating histone H2AX in response to DNA damage, 
making it gH2AX 222.  It is possible that gH2AX was hyperphosphorylated due to 
overactivation of ATM, as was observed in mice 77,217.  From the radiation survival 
experiments, we showed that rad50-mutant zebrafish are radiosensitive.  The increased 
gH2AX seen in rad50 mutants is likely due to either a failure to clear gH2AX due to a 
DNA repair defect, overactivation of ATM, or a combination of both. 
As ATM is regulated posttranslationally through phosphorylation at serine 1981, 
monitoring for ATM over-activation requires a method to differentiate between 
phosphorylated and unphosphorylated ATM 225.  An antibody for phospho-serine 1981 in 
ATM does not exist in zebrafish, but it may be possible to perform mass spectrometry 
instead to determine if ATM is over-activated in the rad50-/- zebrafish 245.  A kinase-
inactive zebrafish ATM has shown to act as a dominant-negative for ATM function in 
both human and zebrafish cells 246.  Constitutively expressing this allele in the rad50-/- 
mutants might mitigate some of the mutant phenotypes as has been observed in mice 
77,217.  Because the rad50-/- zebrafish are the only vertebrate model of biallelic null rad50 
mutations, many more questions can be answered using these zebrafish than with 
missense substitutions due to the possibility of gain-of-function phenotypes, which has 
been posited for the Rad50S allele 77. 
 
Female-to-male sex reversal and seminomas observed in xrcc2 mutants 
xrcc2-/- zebrafish showed female-to-male sex reversal.  xrcc2-/- females were 
rescued using a tp53 zdf1 allele mutant background.  Both of these findings are consistent 






Expression of xrcc2 was significantly higher in the gonads of adult male and 
female wild-type zebrafish than in flank, gut, and head.  In xrcc2-/- male zebrafish, 
expression changes in the gonad showed decreased anti-Müllerian hormone (amh) and 
doublesex and mab-3 related transcription factor 1a (dmrt1a) and increased insulin-like 
growth factor 3 (igf3).  These expression changes are consistent with increased follicle-
stimulating hormone (Fsh) levels, which promotes spermatogenesis in zebrafish 163.  
However, there were no consistently observed histologic differences between wild-type 
and xrcc2-/- testes. 
30% of xrcc2-/- male zebrafish developed seminomas, a testicular germ cell tumor 
(TGCT), by 22.5 months of age.  A seminoma was also observed in a brca2-/- zebrafish 
104.  In humans, 95% of seminoma patients survive for at least 10 years 170.  However, a 
subset of about 3% of seminoma patients have treatment-refractory tumors that do not 
respond to the standard treatment of platinum-based chemotherapy agents (e.g., cisplatin) 
and have a poor prognosis 170–173.  Whole-exome sequencing was performed on 43 TGCT 
tumors; of these 43 TGCTs, 2 were treatment-refractory tumors 172.  Both of these 
treatment-refractory TGCTs contained an XRCC2 mutation, while none of the 
nonresistant tumors contained an XRCC2 mutation 172.  To date, this is the only xrcc2-/- 
model to develop seminomas. 
Because of the whole-exome sequencing results showing that XRCC2 may play a 
role in treatment resistance in TGCTs, the xrcc2-/- seminomas need to be evaluated for 
cisplatin resistance.  The sample size from Litchfield et al. 172 was limited to only 2 





allows us to test what role if any xrcc2 plays in cisplatin resistance in TGCTs, which 
could enable exploration of the resistance mechanism in addition to increasing the sample 
size.  Further, if the tumors are cisplatin-resistant, drug screens could then be performed 
to determine which drugs might be effective for treatment-refractory TGCTs instead. 
The two most commonly mutated genes in TGCTs are KIT and KRAS 172.  Since it 
takes almost two years for the seminomas to develop in the xrcc2-/- males, it may be 
possible to decrease the time for tumorigenesis to occur using activated KRAS under the 
control of a gonad-specific promoter (e.g., vasa or ziwi) 247–249.  Such a model would be 
more beneficial for research if we could decrease the tumor latency and increase the 
percentage of fish that develop tumors.  Mutating an additional gene known to be 
mutated in human TGCTs might also create a more faithful model of human XRCC2-
mutant seminomas. 
 
Zebrafish rad50 and xrcc2 mutants show different phenotypes despite 
similarities in humans 
Despite the high degree of similarity between FA and NBS in humans, the 
zebrafish models of FA and NBS-like disease showed marked differences.  Growth 
retardation and bone marrow failure are clinical features of both diseases, yet only the 
rad50 mutants showed these phenotypes 53–57,61–63.  xrcc2-mutant zebrafish showed 
expression changes consistent with elevated Fsh, a feature of both diseases 69,70.  The 
growth retardation present in the rad50 mutants made gonad dissection impractical, so it 
was not tested if there were similar expression changes present in the rad50 mutants.  





DNA repair defects.  This could stem from the fact that rad50 is involved early in DNA 
DSB repair compared to xrcc2, which is only involved in HDR 3–5.  Since rad50 is 
involved in both NHEJ and HDR, it could explain why the xrcc2 mutants have a much 
less severe phenotype compared to the rad50 mutants, which have many more organ 
systems affected 115. 
 
Issues with missense substitution assay development 
Zebrafish offer several experimental benefits over mammalian organisms to study 
missense substitutions.  mRNAs containing either wild-type sequence or various 
missense substitutions can be injected into one cell stage embryos.  Embryo injection 
assays in zebrafish have been used for sequence variant functional analysis previously 
108,109,250–252.  Davis et al. 253 reviewed the potential that zebrafish possess for analysis of 
human mutations.  Drost and de Wind 110 developed a PCR-based method for generation 
of mRNAs that does not require cloning or sequencing of the variants, which could 
accelerate and reduce the costs for evaluation of many sequence variants in parallel.  
Zebrafish microinjection of mRNAs can therefore be a medium throughput assay, which 
is preferable to painstaking process of generating mice bearing various missense 
substitutions. 
Because of some biological differences between mammals and zebrafish, it was 
not possible to assay human missense substitutions using the zebrafish models.  The main 
difficulty was that maternal effect was present for both rad50 and xrcc2, which precluded 






Maternal effect masks early effects of the mutations 
The main issue with using zebrafish to study early development is maternal effect, 
wherein mRNA and protein for some genes are maternally provided in the oocyte, 
meaning that zebrafish embryos that are genetically null are phenotypically wild type due 
to the maternal supply of wild-type mRNA 254.  All of the DSB repair genes appear to 
have maternal effect; the presence of maternal mRNA for both rad50 and xrcc2 was 
confirmed via quantitative reverse transcription polymerase chain reaction (data not 
shown).  To perform the mRNA injection assays, maternal mRNA cannot be present.   
The wild-type maternal RNA/protein masks any decrease in function that the variants 
might cause in the assays due to the wild-type maternal protein complementing the 
mutant phenotypes. 
Using homozygous mutant mothers is the easiest way to bypass maternal effect.  
However, it was not possible to generate fertile rad50 mutants since the mutants suffered 
from growth retardation.  Further, there is evidence from mice that Rad50 hypomorphic 
mutants have severe fertility defects 77,217.  For xrcc2, mutant females were eventually 
recovered, but other issues prevented assay development from occurring; these will be 
discussed later. 
Mutating tp53 has been shown to partially rescue Rad50 and FA mutants 76,104,121.  
However, only the xrcc2-mutant phenotype, and not the rad50-mutant phenotype, could 
be partially rescued through tp53 mutation.  xrcc2-/- females were rescued by utilizing the 
dominant-negative zdf1 mutant allele of tp53.  Despite evidence that tp53 partially 
rescues Rad50S/S mice, no differences were observed between rad50-/- zebrafish and 





Since mutating tp53 did not rescue the rad50-/- zebrafish, several different 
approaches, using transgenes and gene targeting, were attempted to try to bypass 
maternal effect.  An approaching using the ubiquitin promoter targeted to a phiC31 site 
that has been verified to express ubiquitin-driven transgenes was attempted to drive 
human RAD50 in zebrafish 255,256.  The goal was to recover a chimera that did not express 
RAD50 in the germline but was normal sized.  However, the fish that were rad50 mutants 
and had incorporated the transgene were all growth retarded (data not shown).  The 
approach we felt had the best chance to work was to make a rad50 floxed allele and use 
an oocyte-specific promoter, e.g. ziwi, to drive Cre 247.  This approach would bypass 
maternal effect without affecting other organs in the female zebrafish.  It also would 
remove rad50 after crossing over, decreasing the chance to negatively affect fertility 247.  
However, when this work was attempted, little had been done on gene targeting in 
zebrafish, so we were never able to recover a rad50 allele that included LoxP sites.  
Because each of the transgenic approaches to bypass maternal effect failed, we were 
unable to bypass maternal effect for rad50, meaning we were unable to conduct our 
assays of missense substitutions in human RAD50. 
Because of maternal effect, we were unable to observe any mutant phenotypes 
prior to 5 dpf.  Multiple experiments were attempted earlier in development, but no 
different in phenotype was observed in the rad50-/- zebrafish compared to wild-type 
siblings.  These assays included whole-mount immunofluorescence for cleaved Caspase-
3, a marker of apoptosis, following irradiation with doses ranging from 10-100 Gy of 
ionizing X-rays 111.  Cleaved Caspase-3 staining showed no difference between rad50 





The amount of cleaved Caspase-3 decreased considerably each day and was nearly 
undetectable by 4 dpf even with 100 Gy of radiation due to development of the notochord 
257.  Another assay that was attempted was using 5-bromo-2'-deoxyuridine (BrdU) to 
monitor differences in cell proliferation at 3 dpf.  However, there was no difference in 
BrdU in rad50 mutants compared to wild-types.  The last assay that was attempted 
radiation-induced cell cycle arrest.  This assay was not feasible in later embryos because 
approximately 90% of the cells were in G0/G1 at 3 dpf, so we did not observe differences 
in cell cycle arrest between rad50-/- and wild-types or between wild-types that received 
different doses of radiation (from 15-75 Gy of ionizing X-rays) (data not shown). 
 
xrcc2 loss appears to only affect the gonad 
While mutation of tp53 eventually allowed for the recovery of tp53zdf1/zdf1; xrcc2-/- 
females, thus bypassing maternal effect for xrcc2, assays for human XRCC2 sequence 
variants were still not possible.  Zebrafish rely more heavily on NHEJ compared to HDR 
to repair DSBs 258,259.  This is likely related to the fact that zebrafish lack brca1 and have 
an incomplete bard1 that lacks the N-terminal RING domain required for 
heterodimerization with brca1 (SVT unpublished) 28,260.  There is a hypothesis in the field 
that BRCA1 inhibits NHEJ, which is supported by evidence in mice that mutation of 
53BP1, an important NHEJ factor that also blocks strand resection, an important process 
in HDR, partially rescues Brca1-mutant cells 261. 
The expression of xrcc2 appears to be limited to the gonad in adult zebrafish.  
Prior to our study of xrcc2, there have been no previous studies of xrcc2 in zebrafish.  





development in zebrafish. The limited expression of xrcc2 could stem from the fact that 
zebrafish lack brca1, leading to a globally reduced dependence on HDR relative to NHEJ 
260,262,263. 
A previous study reported repair of damaged GFP at relatively high frequency, 
and the amount of functional EGFP produced was significantly decreased following 
injection of a rad51 morpholino 113.  However, we were not able to replicate these 
findings.  Using plasmids provided by the Jun Chen lab, we were unable to generate 
EGFP repair at levels even remotely close to what Liu et al. 113 reported.  Additionally, 
xrcc2 maternal-zygotic mutants showed only a 13% reduction in EGFP compared to 
wild-types (data not shown).  This finding sits in stark contrast to the roughly 3-fold 
decrease that was observed with the injection of the rad51 morpholino 113.  Since xrcc2 is 
a rad51 paralog, it would seem logical that a similar decrease in EGFP production would 
be observed in the xrcc2 mutants compared to the rad51 morpholino-injected fish.  
However, there are a few possible explanations for the differences observed between our 
study and Liu et al. 113.  First, the zebrafish field has moved away from morpholinos 
because of the off-target effects associated with morpholinos that can yield inaccurate 
results 264–267.  Now that rad51 mutants exist for zebrafish, this finding could attempt to 
be replicated in the mutant background 125.  Further, the rad51-mutant zebrafish show a 
more severe mutant phenotype that affects many more organ systems than observed in 
the xrcc2-mutant zebrafish, which could relate to the limited expression of xrcc2 in 
zebrafish.  In humans, RAD51 is the only dominant FA gene 79,80.  Lastly, the difference 
in findings could stem from that fact that we were unable to replicate any of their 





Another potential assay explored for the xrcc2 mutants was sensitivity to DNA 
damaging agents, including DNA crosslinking agents and ionizing X-rays, which cause 
DSBs.  The irs1 cell line, where XRCC2 was first discovered, is sensitive to both types of 
DNA damaging agents 43.  Differences in apoptosis were examined following treatment 
with DNA damaging agents, using whole-mount immunofluorescence for cleaved 
Caspase-3 111.  The DNA damaging agents used were ionizing radiation and cisplatin, a 
DNA crosslinking chemotherapy drug.  Despite the sensitivity of the irs1 cells to these 
agents, no differences in cleaved Caspase-3 were found in the xrcc2 mutants compared to 
wild-types (data not shown). 
Given the lack of discernible phenotypes outside of the gonads in the xrcc2-
mutant zebrafish and the limited expression of xrcc2 in wild-type adult zebrafish, the 
possibility exists that xrcc2 is dispensable outside the gonad.  Further, the xrcc2 mutants 
show a less severe phenotype when compared to brca2 mutants, which is also involved in 
HDR 104.  The tumor spectrum in the brca2 mutants includes seminomas, a germ cell 
tumor, papillary cystadenomas, and undifferentiated stromal cell tumors, both somatic 
cell tumors.  Comparatively, xrcc2 mutants only develop seminomas.  Since the mutant 
phenotypes in xrcc2, including both the sex reversal phenotype and tumorigenesis, are 
largely restricted to the germ cells, we hypothesize that xrcc2 may function only in 
crossing over in zebrafish.  All of this occurs in cells that lack BRCA1, which plays a 
central role in DNA repair in most vertebrates, nematodes, and plants 268–270.  Given the 
fact that brca1 is a Fanconi anemia gene, it is logical to hypothesize that other 
compensatory changes might have occurred in concert with the loss of brca1 in zebrafish 





zebrafish 78,104,121,125.  These other potential changes would suggest that the DSB repair 
pathway may function in subtly different ways in zebrafish compared to mammals, 
despite the pathway being largely conserved outside of brca1, which could explain why 
the loss of xrcc2 only appears to affect crossing over 102,260. 
 
Future directions 
Because zebrafish rely so much more heavily on NHEJ to repair DSBs, zebrafish 
were likely not an appropriate model to assay missense substitutions in HDR genes.  The 
xrcc2-mutant zebrafish certainly provided some utility to study the effects xrcc2 plays on 
vertebrate gonad development.  Human cells or the Chinese hamster ovary cell line irs1 
likely would have been a better system to assay XRCC2 mutations; however assays for 
XRCC2 mutations have already been performed in irs1 cells 118. 
Since zebrafish lack brca1, it could be possible to inject human BRCA1 mRNA 
along with BARD1 mRNA or make transgenic zebrafish that express full-length human 
BRCA1 and BARD1 cDNA.  Based on other literature, this might increase HDR in the 
zebrafish and might make the damaged GFP assay more meaningful 261,271.  The 
possibility also exists that xrcc2 loss could be more severe in zebrafish with human 
BRCA1 and BARD1 present due to an increased reliance on HDR. 
Our lab has had success using human cell lines to assay missense substitutions in 
the RING and BRCT domains of BRCA1 (manuscript in revision; bioRxiv 092619).  For 
the RING domain, a mammalian 2-hybrid assay was performed with BRCA1 RING 
fused to GAL4 and BARD1 RING fused to VP16.  The interaction between the RING 





XRCC2 protein exist in complexes, it may be possible to adapt the mammalian 2-hybrid 
approach developed for the BRCA1 RING domain for RAD50, examining interactions 
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